CLARISCAN 376.9 mg/mL (Gadoterate Meglumine INJECTION, SOLUTION) 376.9 mg/mL

Clariscan 376.9 mg/mL is a gadoterate meglumine injection solution used for magnetic resonance imaging (MRI). This contrast agent enhances image clarity during diagnostic procedures, aiding in the detection of abnormalities.

Strength

376.9 mg/mL

Pack Size

10 SYRINGE, PLASTIC in 1 BOX (0407-2943-17) / 15 mL in 1 SYRINGE, PLASTIC

Manufacturer / TM Owner

GE Healthcare

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Clariscan 376.9 mg/mL is primarily used as a contrast agent in MRI scans. It helps to improve the visibility of internal structures, making it easier for healthcare professionals to identify and assess various conditions. This gadoterate meglumine injection is commonly employed in diagnostic imaging to enhance the quality of images, particularly in detecting abnormalities in soft tissues and organs.

Side Effects

When administered intravenously, Clariscan 376.9 mg/mL works by temporarily altering the magnetic properties of tissues, which can enhance the contrast in MRI images. This can lead to clearer and more detailed images, aiding in the diagnosis of various conditions. The effects are typically short-lived, as the contrast agent is quickly eliminated from the body.

Precautions & Warnings

Clariscan 376.9 mg/mL should be used with caution in individuals with a history of allergic reactions to contrast agents. It is important to inform healthcare professionals about any existing medical conditions or allergies before administration. Proper handling and storage are essential to maintain the integrity and effectiveness of the solution.

Avoid Interactions

Clariscan 376.9 mg/mL may interact with certain medications or substances, so it is important to disclose all current medications to a healthcare professional. Alcohol and other substances that affect the central nervous system should be avoided, as they may influence the body's response to the contrast agent.

Frequently Asked Questions

Clariscan 376.9 mg/mL is used as a contrast agent in MRI scans to enhance the visibility of internal structures and detect abnormalities.

Clariscan 376.9 mg/mL is administered intravenously by a healthcare professional during an MRI procedure.

Clariscan 376.9 mg/mL temporarily alters the magnetic properties of tissues, enhancing the contrast in MRI images for clearer diagnostic results.

Individuals with a history of allergic reactions to contrast agents should use Clariscan 376.9 mg/mL with caution and inform their healthcare professional.

Clariscan 376.9 mg/mL may interact with certain medications, so it is important to disclose all current medications to a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.